Skip to content
OpenCapital
Get started

Sylvamo SLVM R&D credit carryforward

R&D credit carryforward at other companies

AZZ logo
AZZAZZ
$970K-80.8%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$6.99M-19.2%
HTF
Heartflow, Inc. Common StockHTFL
$7.63M+7.3%
Nuvation Bio logo
Nuvation BioNUVB
$23.38M+20.6%
Sylvamo logo
SylvamoSLVM
$0-100%
HRO
HarrowHROW
$4.79M+111%

Other financials

Income statement

See full
Revenue$755.0M-8.0%
Gross profit$125.0M-21.4%
Net income-$3.0M-111%
EPS (diluted)-$0.08-112%

Balance sheet

See full
Cash & equivalents$130.0M-15.6%
Total debt$861.0M-3.9%
Total equity$979.0M+7.8%
Total assets$2.8B+2.6%

Cash flow

See full
Operating cash flow-$10.0M-143%
CapEx$49.0M+2.1%
Free cash flow-$59.0M-136%

Valuation

See full
Market cap$1.53B-38.6%
Enterprise value$2.26B-30.7%
P/E15×+6.3×
P/S0.5×-0.2×

Profitability

See full
Gross margin21.3%-3.3pp
Net margin3.1%-4.6pp
FCF margin0.3%-6.6pp

Returns & leverage

See full
Return on equity10.8%-21.0pp
Debt / equity0.9×-0.1×
Current ratio1.4×-0.2×

Where this comes from

Reported directly by Sylvamo in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.

The official record: Sylvamo’s 10-K, filed February 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sylvamo's r&d credit carryforward.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sylvamo's r&d credit carryforward?
Sylvamo (SLVM) reported r&d credit carryforward of $0 in Q4 2025.
What is the long-term trend for Sylvamo's r&d credit carryforward?
Over 3 years (2022 to 2025), Sylvamo's r&d credit carryforward has grown at a -100.0% compound annual growth rate (CAGR), from $7M to $0.
What does r&d credit carryforward mean?
The accumulated value of research and development tax credits that have not yet been utilized to reduce tax liabilities. These carryforwards represent future tax shields that can improve cash flow and net income in subsequent periods.